Capricor Therapeutics Inc CAPR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CAPR is a good fit for your portfolio.
News
-
Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
-
Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy
-
CORRECTION: Capricor Therapeutics
-
Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy
-
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
-
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
-
Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
-
Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Trading Information
- Previous Close Price
- $4.43
- Day Range
- $4.32–4.56
- 52-Week Range
- $2.68–8.22
- Bid/Ask
- $4.38 / $4.81
- Market Cap
- $139.75 Mil
- Volume/Avg
- 276,093 / 419,444
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.58
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 102
- Website
- https://www.capricor.com
Comparables
Valuation
Metric
|
CAPR
|
IMVT
|
ICVX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 7.52 | 6.86 | 3.30 |
Price/Sales | 4.58 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
CAPR
IMVT
ICVX
Financial Strength
Metric
|
CAPR
|
IMVT
|
ICVX
|
---|---|---|---|
Quick Ratio | 1.53 | 13.18 | 17.59 |
Current Ratio | 1.57 | 13.70 | 18.06 |
Interest Coverage | — | — | — |
Quick Ratio
CAPR
IMVT
ICVX
Profitability
Metric
|
CAPR
|
IMVT
|
ICVX
|
---|---|---|---|
Return on Assets (Normalized) | −32.31% | −44.70% | −29.30% |
Return on Equity (Normalized) | −164.41% | −49.06% | −31.87% |
Return on Invested Capital (Normalized) | −133.20% | −53.44% | −34.69% |
Return on Assets
CAPR
IMVT
ICVX
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Mqtmfglwty | Wwnp | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Pbsppyhf | Yhydy | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Qbccpkz | Bjvqw | $118.7 Bil | |||
Moderna Inc
MRNA
| Chvlxhhst | Zlxf | $46.8 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Spwbyhrt | Smhhrz | $29.7 Bil | |||
argenx SE ADR
ARGX
| Spzrwlbgd | Qxqk | $29.3 Bil | |||
BioNTech SE ADR
BNTX
| Wnxydmz | Rtrb | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Pjmwzrcrh | Yswgblz | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Bhkqylhs | Dycvd | $15.0 Bil | |||
Incyte Corp
INCY
| Qdmkypy | Fcszy | $13.5 Bil |